Why Galectin Therapeutics, Inc. Shares Soared

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Galectin Therapeutics (NASDAQ: GALT  ) , a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer and fibrotic diseases, soared as much as 28% after issuing a press release regarding its phase 1 study of GR-MD-02 in fatty liver disease (nonalcoholic steatohepatitis, or NASH) with advanced fibrosis.

So what: According to Galectin's press release, the company will be releasing results from the first cohort of its phase 1 clinical study which enrolled eight patients on Monday, March 31. Galectin CEO Peter Traber will lead a webcast and conference call the following day, April 1, at 8:30 a.m. ET. The thinking from investors is that a webcast and conference call from Traber is unlikely if GR-MD-02 didn't meet the company's expectations. Therefore, there's a good chance GR-MD-02 was safe and tolerable for this initial cohort of patients.

Now what: The real story here is that investors are chomping at the bit to get their hands on the next great therapy that could treat NASH, a disease that leads to fatty buildup in the liver and can potentially lead to cirrhosis and/or liver cancer. There are approximately 6 million people in this country with a more severe form of NASH, so the market potential for a NASH therapy is enormous. Investors also have Intercept Pharmaceuticalsovernight quadruple on their minds following its phase 2 study results in January, so Galectin shareholders are hoping for much of the same. The reality here is that we're merely looking at safety data and biomarker identification, with efficacy data set to come later down the road. Investors will want to keep that in mind when assessing this initial phase 1 data when it's reported early next week.

Galectin may be soaring today, but chances are it'll have a hard time keeping up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 24, 2014, at 1:00 PM, rwestberg wrote:

    Your recent pronouncements regarding GALT & ICPT have me wondering about the depth of your investigations . You have given a great amount of support to ICPT i.e. recently stating that ICPT was still a buy when the stock was at $ 450. It’s now under $ 300. In contrast you diminished the results of the upcoming webinar by GALT’s President, Dr Traber BEFORE that event even occurred. How brazen.

    I feel that several facts regarding NASH are pertinent. 70 % of people with NASH will NOT show any symptoms and they will never have any health problems associated with the disease. 30 % of the people will have serious health problems as their NASH develops into liver cirrhosis. It’s then academic concerning stopping their NASH problem.

    In other words people aren’t going to be treated for a problem they have no way to know they have. The “bigger picture” is to have a drug that will treat liver cirrhosis and reverse it including the NASH problem..

    In this light the contrast between ICPT & GALT is glaring. To my knowledge ICPT is making no claims of reversing liver cirrhosis but only stopping NASH. GALT is proposing a drug to not only stop liver cirrhosis but to reverse it. Their claims are backed up by 100 % success with their animal studies and very positive results in their first part of their Phase 1 Clinical Test.

    I would suggest that you contact the principals at GALT and find out “the rest of the story”. Please contact GALT’s Chief Executive, Jim Czirr at

    208 263-6695

    Regards,

    Ralph Westberg

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2889302, ~/Articles/ArticleHandler.aspx, 12/20/2014 8:58:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement